Twin City Private Wealth LLC Has $428,000 Stock Holdings in Veeva Systems Inc. (NYSE:VEEV)

Twin City Private Wealth LLC raised its stake in shares of Veeva Systems Inc. (NYSE:VEEV) by 2.9% during the 4th quarter, HoldingsChannel reports. The firm owned 2,036 shares of the technology company’s stock after purchasing an additional 58 shares during the quarter. Twin City Private Wealth LLC’s holdings in Veeva Systems were worth $428,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in VEEV. Principal Financial Group Inc. grew its holdings in Veeva Systems by 138.9% during the third quarter. Principal Financial Group Inc. now owns 2,179,284 shares of the technology company’s stock valued at $457,366,000 after purchasing an additional 1,267,061 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Veeva Systems by 73.2% in the third quarter. JPMorgan Chase & Co. now owns 2,558,592 shares of the technology company’s stock valued at $536,972,000 after acquiring an additional 1,081,501 shares during the period. Wealthfront Advisers LLC boosted its position in shares of Veeva Systems by 29,760.5% in the fourth quarter. Wealthfront Advisers LLC now owns 1,048,700 shares of the technology company’s stock valued at $220,489,000 after acquiring an additional 1,045,188 shares during the period. FMR LLC boosted its position in shares of Veeva Systems by 25.7% in the third quarter. FMR LLC now owns 2,981,244 shares of the technology company’s stock valued at $625,674,000 after acquiring an additional 610,021 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in shares of Veeva Systems in the fourth quarter valued at approximately $95,710,000. Institutional investors and hedge funds own 88.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on VEEV shares. Evercore ISI increased their price objective on Veeva Systems from $220.00 to $245.00 and gave the company an “in-line” rating in a research report on Friday, December 6th. Piper Sandler increased their price objective on Veeva Systems from $280.00 to $290.00 and gave the company an “overweight” rating in a research report on Friday, December 6th. Barclays increased their price objective on Veeva Systems from $260.00 to $275.00 and gave the company an “overweight” rating in a research report on Friday, December 6th. Stephens reissued an “overweight” rating and issued a $280.00 price objective on shares of Veeva Systems in a research report on Thursday, March 6th. Finally, Mizuho initiated coverage on Veeva Systems in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $275.00 price objective for the company. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $256.52.

Veeva Systems Stock Performance

Shares of NYSE VEEV opened at $236.98 on Monday. The stock has a market cap of $38.47 billion, a PE ratio of 58.51, a PEG ratio of 1.89 and a beta of 0.88. The business has a fifty day moving average of $229.24 and a two-hundred day moving average of $222.25. Veeva Systems Inc. has a 52-week low of $170.25 and a 52-week high of $258.93.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.